ClinicalTrials.gg
CompletedNCT04436133Updated May 6, 2022

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

A Phase 2 interventional study of Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) and 9-valent HPV vaccine(Gardasil 9) in HPV Infection and HPV-Related Cervical Carcinoma, sponsored by National Vaccine and Serum Institute, China. Completed at 1 site in China. Open to female participants aged 18 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by National Vaccine and Serum Institute, China (part of Sinopharm) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 26 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 65 studies in Papillomavirus Infections with a site in China — 23 open to participants now, 36 under way, 10 of them phase 3. Papillomavirus Infections · China.

Enrollment
23rd of 42
480 · median 550
Started
2020
with 5 others
Phase 2
7 of 65
2 open now
Registered
18th of 65
by date
Lead sponsor
4 of 65
National Vaccine and Serum Institute, China

Among the 65 studies in Papillomavirus Infections with a site in China, this one is the 23rd largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2020, is one of 7 in phase 2, and was the 18th registered.

Papillomavirus Infections

577 studies on the registry are indexed under Papillomavirus Infections; 131 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

23 of the 65 studies in Papillomavirus Infections with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 85 Papillomavirus Infections studies recruiting now, 38 (45%) set no upper age limit and 42 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 26 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Papillomavirus Infections with a site in China, or all of them as a file.
02

Study summary

A total of 480 Chinese women aged 18-26 years old were enrolle,experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or control vaccine according to the 0, 2, and 6 months immunization program.

03

Conditions studied

  • HPV Infection
  • HPV-Related Cervical Carcinoma
04

Who can participate

Ages eligible
18 Years to 26 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Chinese women aged 18-26 who can provide legal identification;
  2. The subject has the ability to understand the research procedure and sign an ;
  3. Subjects have the ability to read, understand, fill out diary cards/contact cards and other research application forms and promise to participate in regular follow-up as required by the research;
  4. No previous history of HPV vaccination, no participation in HPV vaccine clinical trials, and no plans to receive HPV vaccine during the study period; The subject was not breastfeeding or pregnant (negative urine pregnancy test), did not have a birth plan within 7 months of enrollment; and from day 1 of the last menstrual cycle to day 0 of the study, did not have sex with men or with men Effective was used during sex and no contraceptive failures occurred (examples of contraceptive failure include male condom rupture during sex). And agreed to continue to take effective contraceptive measures within the first 7 months after participating in the study (effective contraceptive measures include: oral contraceptives, hormone patches, intrauterine devices, condoms, cervical caps, etc.).

First dose exclusion criteria:

  1. Previous history of cervical lesions (such as abnormal cervical cancer screening, history of CIN disease) or history of hysterectomy surgery (vaginal or total hysterectomy) or history of pelvic radiation therapy; previous history of external genital diseases (such as vulvar epithelium) Neoplasia, intraepithelial neoplasia and genital warts, etc.);
  2. Previous history of severe allergic reactions requiring medical intervention for any vaccine or drug (including yeast) (eg: anaphylactic shock, allergic throat edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction) Wait);
  3. Immune function is impaired or has been diagnosed with congenital or acquired immunodeficiency, (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile Rheumatoid arthritis (JRA), inflammatory bowel disease or other diseases;
  4. Long-term treatment with agents, such as: long-term (more than 2 weeks in a row) treatment with (eg, prednisone or similar drugs);
  5. Receive any immunoglobulin or blood products within 3 months before vaccination, or plan to receive such products before the 7th month of the study;
  6. Received inactivated vaccine or recombinant vaccine within 14 days before vaccination, or received any within 28 days;
  7. Loss of spleen or functional spleen, and removal of spleen or spleen caused by any situation;
  8. Has been diagnosed with a disease that may interfere with the progress or completion of the study, such as: suffering from severe cardiovascular disease (pulmonary heart disease, pulmonary edema), severe liver and kidney disease, diabetes with complications, etc.; or has been diagnosed with Infectious diseases, such as: active tuberculosis, , , etc.;
  9. A history of convulsions, epilepsy, encephalopathy, mental illness, family history of mental illness, etc.;
  10. There are thrombocytopenia or other coagulation disorders that can be to intramuscular injection; 11.3 days before the vaccination, suffering from acute disease or in the acute onset of chronic disease or using antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, cetaxidine Tirizine, etc.);

12.Body temperature before inoculation≥37.3℃(armpit body temperature); 13. People who have a systolic blood pressure ≥140mmHg and/or a diastolic blood pressure ≥90mmHg before enrollment; 14. Participate or plan to participate in other clinical trials (drugs, vaccines and medical devices) during the study; 15. Plan to move out of the local area before the end of the study or leave the area for a long time during the scheduled study visit;

Exclusion criteria for second and third doses of vaccination:

  1. Before vaccination (the day of vaccination), pregnant or urine pregnancy test (HCG) is positive; Note: If the subject chooses to terminate the pregnancy, at least 6 weeks after the end of pregnancy and the urine pregnancy test is negative on the day before the vaccination, or the medical certificate of termination of pregnancy issued after the end of pregnancy indicates that HCG levels have returned to normal levels, you can continue Vaccination; if you choose to continue pregnancy, you will not be vaccinated for subsequent doses.
  2. Newly discovered or newly occurred conditions that meet the first dose exclusion criteria (except Articles 1 and 13);
  3. Other serious adverse events: The researcher decides whether to terminate the test vaccination according to his treatment needs;
  4. The investigator assessed any other reasons why the vaccination for the trial should be terminated.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    vaccine group

    Biological: Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

  • Active comparator
    Positive control group

    Biological: 9-valent HPV vaccine(Gardasil 9)

Interventions

  • BiologicalBiological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

    Drug pages: Biological Products · Recombinant Human Papillomavirus 11-valent Vaccine

    Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle

  • Biological9-valent HPV vaccine(Gardasil 9)

    Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle

06

What researchers measure

Primary outcomes

  1. Anti-HPV neutralizing antibodies GMT

    Time frame: 30 days after full immunization

  2. Anti-HPV neutralizing antibody positive conversion rate(after full immunization 30 days)

    Time frame: 30 days after full immunization

  3. Collect all SAEs

    Vaccine-related and unrelated

    Time frame: through study completion, an average of 13 months

  4. Collect AEs incidence

    Vaccine-related and unrelated

    Time frame: Within 30 minutes of injection

  5. Collect AEs incidence

    All AEs: incidence of AEs related to vaccines and unrelated The rate of Solicited for AE Non-collective AEs: incidence of AEs related to vaccines and unrelated AE level 3 and above: incidence of vaccine-related and unrelated AEs

    Time frame: Within 30 days after inoculation

  6. collect AEs leading subject to withdrawal

    Incidence of vaccine-related and unrelated AEs

    Time frame: through study completion, an average of 13months

  7. collect All pregnancy conditions and pregnancy outcomes

    collect pregnant woman Anti-HPV neutralizing antibody positive conversion rate and Anti-HPV neutralizing antibodies GMT

    Time frame: through study completion, an average of 13 months

07

Study locations

1 site
  • Liucheng Center for Disease Control and Prevention
    Liuzhou, Guangxi, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Mar 2022, 20 months.

Of 41 phase 2 interventional studies under Papillomavirus Infections, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 77. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2020
First posted
Jun 17, 2020
StartActual
Jun 20, 2020
Primary completionActual
Mar 1, 2022
CompletionActual
Mar 1, 2022
Last update
May 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04436133
Collaborators
Chengdu Institute of Biological Products Co.,Ltd., Simoon Record Pharma Information Consulting Co., Ltd., Guangxi Center for Disease Control and Prevention, Beijing Kantorico Statistical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Jun 20, 2020
Primary completion
Mar 1, 2022
Completion
Mar 1, 2022
Last update
May 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Biological Products · Recombinant Human Papillomavirus 11-valent Vaccine

Start the discussion